Bank Pictet Cie (asia) Ltd buys $1,028,447 stake in Celgene Corporation (CELG)

Celgene Corporation (CELG) : Bank Pictet Cie (asia) Ltd scooped up 2,460 additional shares in Celgene Corporation during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Aug 10, 2016. The investment management firm now holds a total of 9,070 shares of Celgene Corporation which is valued at $1,028,447.Celgene Corporation makes up approximately 0.62% of Bank Pictet Cie (asia) Ltd’s portfolio.

Other Hedge Funds, Including , Friedberg Investment Management boosted its stake in CELG in the latest quarter, The investment management firm added 1,080 additional shares and now holds a total of 25,870 shares of Celgene Corporation which is valued at $2,933,399. Celgene Corporation makes up approx 1.35% of Friedberg Investment Management’s portfolio.Zwj Investment Counsel Inc boosted its stake in CELG in the latest quarter, The investment management firm added 1,835 additional shares and now holds a total of 216,409 shares of Celgene Corporation which is valued at $24,629,508. Celgene Corporation makes up approx 2.46% of Zwj Investment Counsel Inc’s portfolio.Argent Trust Co boosted its stake in CELG in the latest quarter, The investment management firm added 279 additional shares and now holds a total of 6,535 shares of Celgene Corporation which is valued at $754,989. Celgene Corporation makes up approx 0.32% of Argent Trust Co’s portfolio.Lucas Capital Management reduced its stake in CELG by selling 625 shares or 2.8% in the most recent quarter. The Hedge Fund company now holds 21,709 shares of CELG which is valued at $2,435,533. Celgene Corporation makes up approx 1.68% of Lucas Capital Management’s portfolio.Fisher Asset Management boosted its stake in CELG in the latest quarter, The investment management firm added 5,968 additional shares and now holds a total of 204,128 shares of Celgene Corporation which is valued at $20,772,065. Celgene Corporation makes up approx 0.04% of Fisher Asset Management’s portfolio.

Celgene Corporation opened for trading at $111.83 and hit $112.93 on the upside on Friday, eventually ending the session at $112.16, with a gain of 0.03% or 0.03 points. The heightened volatility saw the trading volume jump to 29,16,819 shares. Company has a market cap of $86,937 M.

On the company’s financial health, Celgene Corporation reported $1.44 EPS for the quarter, beating the analyst consensus estimate by $ 0.05 according to the earnings call on Jul 28, 2016. Analyst had a consensus of $1.39. The company had revenue of $2754.00 million for the quarter, compared to analysts expectations of $2709.02 million. The company’s revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.23 EPS.

Many Wall Street Analysts have commented on Celgene Corporation. Stifel Initiated Celgene Corporation on Jul 15, 2016 to “Buy”, Price Target of the shares are set at $138.

Celgene Corporation (Celgene) together with its subsidiaries is an integrated biopharmaceutical company engaged primarily in the discovery development and commercialization of therapies for the treatment of cancer and inflammatory diseases through gene and protein regulation. The Company’s primary commercial stage products include REVLIMID (lenalidomide) ABRAXANE POMALYST/IMNOVID VIDAZA azacitidine for injection (generic version of VIDAZA) THALOMID (sold as THALOMID or Thalidomide Celgene outside the United States) OTEZLA (apremilast) and ISTODAX (romidepsin). Celgene is involved in research in a range of scientific areas designed to deliver therapies targeting areas including intracellular signaling pathways protein homeostasis and epigenetics in cancer and immune cells immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Leave a Reply

Celgene Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Celgene Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.